Deals
Deals dated after 30 September 2026 are still being collected.
Columns
4 of 4 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 2026 | Cy Biopharma | – | Ensysce Biosciences | Acquisition | Financial adviser to Ensysce Biosciences (acquirer) | Completed | – | Biotech+1 | Troutman Pepper Locke (buy-side)Orrick (sell-side)Wedbush Securities (sell-side)H.C. Wainwright & Co. | Ensysce Biosciences acquisition of Cy Biopharma |
| Jul 2026 | Vidya Therapeutics | – | Processa Pharmaceuticals | Acquisition | Financial adviser and fairness opinion to Processa Pharmaceuticals (acquirer) | Completed | – | Biotech+1 | Leerink Partners (sell-side)Cooley (sell-side)Katten Muchin Rosenman (buy-side) | Processa Pharmaceuticals acquisition of Vidya Therapeutics |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Financial adviser to NextCure (acquirer) | Announced | – | Biotech+1 | Sullivan & CromwellSidley AustinGibson Dunn (sell-side)Wedbush Securities (sell-side) | NextCure and Avere Therapeutics merger |
| Mar 2026 | Unleash-owned rights to UIO-524, UIO-525 and UIO-526 | Unleash Immuno Oncolytics | TransCode Therapeutics | Asset sale | Financial adviser | Pending | – | Biotech+2 | TransCode Therapeutics acquisition of Unleash-owned rights to UIO-524, UIO-525 and UIO-526 |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.
Most often across the table
- Wedbush Securities2 dealsCompare
- Leerink Partners1 dealCompare
- Cooley1 dealCompare
- Orrick
1 dealCompare - Gibson Dunn
1 dealCompare
Firms advising the other side of the same deals.